Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults
The National Health Care Institute has carried out an assessment whether patiromer (Veltassa®) is interchangeable with a medicinal product already included in the Medicine Reimbursement System (GVS).
Registration
Patiromer (Veltassa®) is registered for the treatment of hyperkalaemia in adults. The manufacturer is asking for reimbursement for a sub-group within the broad indication for which patiromer is registered, i.e., patients with chronic kidney disease (CKD) stage 3 or 4 with chronic hyperkalaemia which requires treatment with RAAS inhibitors.
Advice on inclusion in the GVS
We advise the Minister of VWS to include patiromer together with CPS in a new cluster on List 1A of the GVS. The applicable standard dose for patiromer is 8.4 g/day. The standard dose of CPS is 45 g/day. Should the Minister decide to include this product in the GVS, we advise linking its reimbursement to the following condition.
Condition
Only for an insured person aged eighteen years or older, with chronic kidney disease (CKD) stage 3
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.